**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 91521

**Manuscript Type:** MINIREVIEWS

**Blastomas of the digestive system in adults: A review**

Liu Y *et al*. Review of adult GI blastomas

Yu Liu, Tony El Jabbour, Jonathan Somma, Yukihiro Nakanishi, Saverio Ligato, Hwajeong Lee, Zhi-Yan Fu

**Yu Liu, Jonathan Somma, Zhi-Yan Fu,** Department of Pathology, LSU Health Sciences Center School of Medicine, New Orleans, LA 70112, United States

**Tony El Jabbour, Saverio Ligato,** Department of Pathology, Hartford HealthCare, Hartford, CT 06102, United States

**Yukihiro Nakanishi,** Department of Pathology, Moffitt Cancer Center, Tampa, FL 33612, United States

**Hwajeong Lee,** Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY 12208, United States

**Author contributions:** Liu Y and Fu ZY are acknowledged for their substantial contributions to drafting the work, conducting a comprehensive literature review for all discussed sections, revising critically important intellectual content, and giving final approval to the published version; Jabbour T and Lee H are credited for providing guidance on the topic; Jabbour T, Nakanishi Y, and Ligato S are acknowledged for their contributions to pathology imaging; Somma J is credited with aiding in the final polishing of content language; All authors have actively participated in the creation of the manuscript and agree with the final version of the manuscript.

**Corresponding author: Zhi-Yan Fu, MD, Attending Doctor,** Department of Pathology, LSU Health Sciences Center School of Medicine, 1901 Perdido St, New Orleans, LA 70112, United States. zfu@lsuhsc.edu

**Received:** January 1, 2024

**Revised:** February 3, 2024

**Accepted:** March 25, 2024

**Published online:**

**Abstract**

Blastomas, characterized by a mixture of mesenchymal, epithelial, and undifferentiated blastematous components, are rare malignant neoplasms originating from precursor blast cells. This review focuses on digestive system blastomas in adult patients, including gastroblastoma, hepatoblastoma, and pancreatoblastoma. Gastroblastoma is a biphasic, epitheliomesenchymal tumor, with only sixteen cases reported to date. In addition to the characteristic histology, metastasis-associated lung adenocarcinoma transcript 1 - glioma-associated oncogene homolog 1 gene fusion is typical, although recently novel ewing sarcoma breakpoint region 1 - c-terminal binding protein 1 and patched 1 - glioma-associated oncogene homolog 2 fusions have been described. Hepatoblastoma is exceptionally rare in adults and can show a variety of histologic patterns which may cause diagnostic difficulty. Pancreatoblastoma, primarily a pediatric tumor, displays acinar differentiation and squamoid nests with other lines of differentiation also present, especially neuroendocrine. Diagnostic approaches for these blastomas include a combination of imaging modalities, histopathological examination, and molecular profiling. The treatment generally involves surgical resection, which may be supplemented by chemotherapy or radiotherapy in some cases. Prognoses vary with gastroblastoma generally showing favorable outcomes post-surgery whereas hepatoblastoma and pancreatoblastoma often have poorer outcomes, particularly in the setting of metastases. This review highlights the complexity of diagnosing and managing these rare adult blastomas as well as the need for ongoing research to better understand their pathogenesis and improve treatment strategies.

**Keywords:** Adult blastomas; Gastroblastoma; Hepatoblastoma; Pancreatoblastoma; Digestive system

Liu Y, El Jabbour T, Somma J, Nakanishi Y, Ligato S, Lee H, Fu ZY. Blastomas of the digestive system in adults: A review. *World J Gastrointest Surg* 2024; In press

**Core tip:** Adult digestive system blastomas, including gastroblastoma, hepatoblastoma, and pancreatoblastoma, are rare neoplasms with less than a hundred cases reported for each type. They have nonspecific clinical presentations and imaging findings. Gastroblastoma diagnosis hinges on biphasic histology and the metastasis-associated lung adenocarcinoma transcript 1 - glioma-associated oncogene homolog 1 gene fusion. Hepatoblastoma recapitulates the different embryological stages of liver development and can be epithelial or mixed epitheliomesenchymal. Pancreatoblastoma demonstrates multidirectional differentiation and contains squamoid nests. Surgical resection is the primary treatment for these tumors with adjuvant chemotherapy or radiotherapy in some cases. Prognoses vary, with gastroblastoma typically having better post-surgical outcomes. In contrast, hepatoblastoma and pancreatoblastoma frequently recur and metastasize.

**INTRODUCTION**

A blastoma is a malignant neoplasm consisting of a combination of mesenchymal, epithelial, and undifferentiated blastematous components. It originates from precursor cells called blasts. Blastomas arise at a variety of sites, and typical examples include medulloblastoma and neuroblastoma. However, the primary digestive system blastomas, hepatoblastoma, pancreatoblastoma, and gastroblastoma, are uncommon, and the literature on these tumors is limited, particularly for cases arising in adults. In fact, no comprehensive resource is presently available. Thus, we aim to present a thorough review of digestive system blastomas in adults which, among other things, will highlight up to date information regarding the complexity of diagnosis, molecular pathogenesis, and management.

Gastroblastoma is a rare tumor, first described by Miettinen *et al*[1] in 2009. It was added to the World Health Organization (WHO) Classification of Tumors of the Digestive System in 2019. Only sixteen cases have been reported to date, most occurring in young adults. However, six have been reported in patients over 30, and the oldest reported case was in a 74-year-old[2]. Gastroblastoma is an epitheliomesenchymal neoplasm primarily developing in the gastric body and antrum[3] . Diagnosis typically relies on the presence of the metastasis-associated lung adenocarcinoma transcript 1 - glioma-associated oncogene homolog 1 (*MALAT1-GLI1*) gene fusion and its biphasic (epitheliomesenchymal) histology[3]. However, recent discoveries, such as the ewing sarcoma breakpoint region 1 - c-terminal binding protein 1 (*EWSR1-CTBP1*)gene fusion in a patient with Wiskott-Aldrich syndrome[4] and the patched 1 - glioma-associated oncogene homolog 2 (*PTCH1-GLI2)* gene fusion[5,6], suggest more genetic diversity than was originally thought.

Hepatoblastoma accounts for 79% of all pediatric malignant liver tumors. Almost 90% of tumors appear before the age of 5, and only 3% occur in patients older than 15 years[7]. Adult hepatoblastoma was first reported by Marx[8] in 1904, and, to date, only about 75 cases of adult hepatoblastoma have been reported[9,10]. Compared to childhood hepatoblastoma, where the 5-year overall survival rates exceed 70%[11,12], adults have a high rate of mortality and poor prognosis, with a 1-year survival rate of 24%[13]. Frequently, patients present with an elevated serum alpha-fetoprotein (AFP) level, which can be used to monitor response to therapy[14]. Although the etiology and pathogenesis of hepatoblastoma are poorly understood, mutations in the *β-catenin* gene, which plays a critical role in the WNT signaling pathway, are commonly observed in both pediatric and adult cases[15]. Due to its rarity in adults, treatment is not as standardized as it is in children, but surgical management is the mainstay of therapy in both populations[12].

Pancreatoblastoma is a rare malignancy, accounting for less than 1% of all exocrine neoplasms of the pancreas[16]. It is characterized by a multilineage cellular proliferation predominantly showing acinar differentiation with distinctive squamoid nests often present. Additionally, neuroendocrine differentiation is common whereas ductal and mesenchymal components are less pronounced[17]. It is most prevalent in pediatric patients, comprising 25% of pancreatic neoplasms in children in the first decade of life[18]. In adults, however, pancreatoblastoma is uncommon, with an incidence rate of just 0.004 per 100000 individuals aged 19 and older, and less than 80 such cases have been reported in the literature to date[19-22]. The genetic landscape of pancreatoblastoma often involves somatic alterations, including the loss of chromosome 11p, which is also implicated in Beckwith-Wiedemann Syndrome, and mutations in the Wnt/β-catenin signaling pathway[16,23,24]. Notably, the clinical course of pancreatoblastoma in adults is more aggressive than in children. Metastasis and/or invasion of adjacent structures contribute to 58% of adult pancreatoblastoma cases, leading to three-year survival rates of less than 40%. This sharply contrasts with the 94.4% 5-year overall survival observed in children[25-27].

**CLINICAL MANIFESTATIONS**

In most cases of gastroblastoma, adult patients present with non-specific symptoms and, in some, the diagnosis is incidental. Reported symptoms include fatigue, abdominal mass, abdominal and/or epigastric pain, and hematemesis[28]. Similarly, hepatoblastoma has non-specific initial clinical manifestations. Pain is the most common symptom including epigastric, abdominal, and low back pain. Fever, vomiting, nausea, anorexia/weight loss, and hepatomegaly/ abdominal mass are also reported. Rarely described manifestations are gastrointestinal bleeding, dyspnea, and lower extremity edema[29]. Pancreatoblastoma is frequently asymptomatic early on; late manifestations include abdominal pain/mass, splenomegaly, obstructive jaundice, fever, diarrhea, melena, weight loss, and occult blood in urine[26].

**LABORATORY/IMAGING FINDINGS**

The imaging findings of blastomas are similar to those of more common tumors of the digestive system. Gastroblastomas appear heterogeneous on abdominal computed tomography (CT)[30], and magnetic resonance imaging (MRI) offers superior soft tissue contrast to clarify the tumor's extent and relationship to adjacent structures. Gastroendoscopy typically reveals an ulcerated, submucosal based mass[4,31]. Although not specific for gastroblastoma, serum markers like Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 (CA19-9) can be elevated in some cases and can be helpful in monitoring for disease recurrence.

Hepatoblastoma may be detected as unifocal or multifocal lesions by imaging. On ultrasound, the tumor is reported as a hyperechoic and solid mass[32]. CT scans and MRIs provide superior delineation of tumor characteristics, extent, and vascular involvement. The use of contrast agents, particularly during the arterial phase, can highlight tumor vascularity. Serum AFP level is usually increased but nonspecific[10,33].

Pancreatoblastomas are single, large, well-delineated, circular or lobulated masses with scattered or aggregate calcifications visible on both CT and MRI. Heterogenous character may reflect a cystic component of some tumors[34]. Contrast imaging shows enhancement in the arterial phase that can mimic a hypervascular neuroendocrine tumor[34-36]. Common bile duct involvement (*i.e.*, dilatation) is apparent in some pancreatic head tumors[34,35,37,38]. Serum AFP has been noted to be increased in 68% cases[18,39] and may be used to monitor the effectiveness of therapy[40]. In the case reported by Li *et al*[35], the patient showed elevated CA19-9 and Cancer Antigen 125 levels[35,38]. Rarely adrenocorticotropic hormone can be secreted from the tumor[40-42].

**CASE REPORTS**

Table 1 summarizes adult gastroblastoma case reports from 2009 to present[43-48]. Patients were on average 37-years-old (range 19-74 years old) at the time of diagnosis. Surgical management was the primary treatment modality, and the gastric antrum was the most common tumor site. Molecular testing was not conducted in the majority of cases, but among those cases tested, all had the *MALAT1-GLI1* gene fusion except for one case with a *PTCH1-GLI2* gene fusion. Although reported follow-up times varied substantially, ranging from 3 months to 14 years, the clinical course was favorable in the majority of patients.

A total of 12 adult hepatoblastoma cases have been reported in the English literature from 2013 to 2023 (Table 2)[49-56]. The average age was 44 years old with a wide range from 22 to 84 years old, and tumors were more frequently right sided. Twelve cases demonstrated elevated serum AFP, and hepatitis B infection and liver cirrhosis were present in 40%. Metastasis at the time of disease presentation was infrequent. Histologically, 75% of cases exhibited mixed epithelial and mesenchymal patterns, and the remainder were purely epithelial. Surgical resection constituted the primary treatment modality, often followed by adjuvant chemotherapy. Follow-up periods were generally short. However, this may be due to the aggressive course of most patients; short term recurrence or metastasis and death were frequent outcomes.

A total of 47 adult pancreatoblastoma cases have been reported since 2018 (Table 3)[57-68]. The average age of affected individuals was 45 years old (range 19 to 75 years old). Half of the patients were diagnosed with metastasis at the time of initial diagnosis, typically to the liver. Tumors arose throughout the pancreas with no discernable pattern. Primary treatment modalities included surgical resection and chemotherapy. Follow-up ranged from several months to a few years, and, although many patients experienced disease recurrence or metastasis, there were several instances of better outcomes during the follow-up period.

**HISTOPATHOLOGY**

Histopathological assessment plays a pivotal role in the diagnosis of blastomas of the digestive system. Gastroblastomas arise within the gastric muscularis propria, and neither component of its biphasic histology displays much cytologic atypia (Figure 1). The epithelial component consists of cells with round uniform nuclei, slightly eosinophilic cytoplasm, and inconspicuous nucleoli. These cells are arranged in sheets, nests, cords, and tubules. Notably, the epithelial component in some cases forms gland- or rosette-like structures that may contain mucin or dense eosinophilic globules. In contrast, the mesenchymal component consists of homogeneous and slender spindle cells often embedded within a myxoid matrix[28,30]. Immunochemistry can be helpful in highlighting these components and confirming the diagnosis. The epithelial component expresses various cytokeratins including AE1/AE3, Cytokeratin 7 (CK7), Cytokeratin 19 (CK19), CAM5.2, and epithelial membrane antigen (EMA). The spindle cells are negative for cytokeratin and express CD56 and CD10. Of diagnostic significance, gastroblastoma does not express CD117 antigen (KIT), Discovered on GIST-1 (DOG1), CD34, Smooth Muscle Actin (SMA), Desmin, synaptophysin, chromogranin, and S100, which separate it from other gastric neoplasms that may be considered in the histologic differential diagnosis[26,29]. Besides its biphasic differentiation, detection of *MALAT1-GLI1* gene fusion was traditionally regarded as confirmatory, although *EWSR1-CTBP1* ( in a pediatric case[4]) and *PTCH1-GLI2* fusions have been described more recently[5,6].

The histology of hepatoblastoma may reflect any stage of hepatic development and, thus, can be quite varied. Some tumors are purely epithelial while others show mixed epithelial and mesenchymal differentiation. The epithelial elements can range in appearance from that of early immature embryonal hepatocytes to a well differentiated hepatocellular phenotype. When present, fetal-type cells are characterized by eosinophilic cytoplasm and distinct cell borders, often arranged in cords or nests reminiscent of, but disorganized as compared to normal liver architecture. In contrast, embryonal components appear more basophilic and densely packed, with a tendency to form pseudoacinar structures. Adding to the potential for diagnostic confusion, ductular (cholangioblastic) differentiation may also be found, and some cases show small cell undifferentiated (SCUD) histology. Mesenchymal components are also varied and can range from fibroblastic to heterologous elements such as bone or cartilage (Figure 2), and some tumors are divided into lobules by non-neoplastic fibrous bands[9,28,29,32,69,70]. There is no definitive immunomarker to distinguish hepatoblastoma from hepatocellular carcinoma, although the latter is positive only for hepatocellular markers, usually occurs in a cirrhotic liver background, and will not contain immature or mesenchymal components. That said, immunohistochemical markers still play a role in the diagnostic and prognostic evaluation of hepatoblastoma[10,28,70,71] with at least some tumor cells, depending on their histologic appearance, expressing AFP, HepPar1, glypican 3, and/or β-catenin (nuclear and cytoplasmic). Pancytokeratins are variably positive in epithelial components, and CK7 and CK19 will highlight cholangioblastic elements when present. Importantly, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1/INI1) is expressed in almost all cases of hepatoblastoma, throughout its varied components. SMARCB1 negative tumors are rare, limited to a subset of those with SCUD histology, and have a poor prognosis.

Histology of adult pancreatoblastoma is characterized by a multilineage cellular proliferation predominantly showing acinar differentiation with distinctive squamoid nests always present. Additionally, neuroendocrine differentiation is common whereas ductal, mesenchymal, or more primitive components are less pronounced. Its acinar component can mimic acinar cell carcinoma as well as the related typical histologic differential diagnosis of pancreatic endocrine tumors and solid pseudopapillary neoplasms too. However, none of these display the prototypical squamoid nests of pancreatoblastoma[22]. While the neuroendocrine component of pancreatoblastoma may be detectable as increased serum levels of hormones, this is uncommon in the adult population[21]. Immunohistochemistry plays a critical role in diagnosing pancreatoblastoma. Acinar differentiation is highlighted with immunolabeling for trypsin, chymotrypsin, and B-cell Lymphoma/Leukemia 10. Neuroendocrine differentiation is evidenced by the expression of Synaptophysin, Chromogranin, and Insulinoma-Associated Protein 1, but should not be diffuse as in the case of pancreatic endocrine tumors. The squamoid component is positive for EMA and beta-catenin (nuclear staining) whereas the latter would be diffusely evident in a solid pseudopapillary neoplasm. Although these tumors may be histologically complex, the synchronous presence of acinar differentiation with immunochemical confirmation plus squamoid nests typically allows for straightforward diagnosis in well sampled tumors[22] (Figure 3).

**MOLECULAR PATHOLOGY**

A molecular hallmark of adult gastroblastoma is the *MALAT1-GLI1* fusion, which is considered essential for diagnosis according to the 2019 WHO classification of digestive system tumors[3]. However, recent literature calls this into question. A pediatric patient with Wiskott-Aldrich syndrome, reported by Koo *et al*[4] in 2021, presented with a gastric submucosal tumor. Despite showing typical histological and immunohistochemical features of gastroblastoma, molecular analysis revealed an *EWSR1-CTBP1* fusion gene. Chen *et al*[5] recently identified a *PTCH1::GLI2* gene fusion in another adult patient with otherwise prototypical gastroblastoma[5,6]. Both cases showed no evidence of the *MALAT1-GLI1* fusion. These genes, *PTCH1* and *GLI2*, are integral to the Hedgehog (Hh) signaling pathway, which plays a vital role in embryonic development[5,6]. These reports suggest a broader spectrum of genetic aberrations in gastroblastoma than was previously thought.

Genomic sequencing studies have established that mutations in the Wnt-β-catenin signaling pathway are prevalent in hepatoblastoma, with alterations in the Catenin Beta 1 (*CTNNB1)* gene detected in about 90% of cases[15,72]. These mutations are central to disease pathogenesis and are often accompanied by changes in other Wnt signaling genes. Additionally, a subpopulation of high-risk hepatoblastomas exhibits alterations in the Nuclear Factor, Erythroid 2 Like 2 (*NFE2L2*) gene, indicating oxidative stress as a contributing factor to cellular transformation and disease progression. The Yap signaling pathway collaborates with β-catenin in tumor development. Nevertheless, the activation mechanism of Yap in hepatoblastoma cases is still unclear, necessitating further studies[72]. Such molecular profiling highlights the complex genetic landscape of hepatoblastoma, may impact patient management presently, and potentially has implications for targeted therapy in the future.

Adult pancreatoblastomas exhibit loss of heterozygosity on chromosome 11p in 86% of cases and alterations in the APC/β-catenin signaling pathway in 67% of cases, including biallelic inactivation of *APC* and activating *CTNNB1* mutations[23]. Interestingly, there is an overlap here with the molecular pathology of hepatoblastoma. Most recently, studies have identified alterations in the Fibroblast Growth Factor Receptor (FGFR) signaling pathway, including *FGFR1* mutations and *FGFR2* rearrangements, in pancreatoblastomas[64]. Additionally, high-level amplification of Myeloid Cell Leukemia Sequence 1 (*MCL1)* has been identified in a small percentage of pancreatoblastoma patients. The patients with *MCL1*-amplified pancreatoblastoma could potentially benefit from targeted MCL1 inhibition[73].

**TREATMENT AND PROGNOSIS**

Surgical resection is the primary treatment approach in all blastomas of the digestive system with chemotherapy or radiotherapy considered for some patients. Generally, post-surgical outcomes are favorable in adult gastroblastoma patients. However, in some cases, local recurrence, metastasis, and death have been reported[30,43]. The case report by Liu *et al*[6] demonstrating successful treatment with endoscopic submucosal dissection offers an insight into less invasive treatment for localized disease[6].

Outcomes are markedly different in adult hepatoblastoma. For unresectable tumors, the one-year survival rate is 0% whereas it is 41% for resectable tumors[69]. Prognosis is dependent on various factors including patient age, extent of resection, and stage of disease. Outcomes are much better in patients who had complete surgical resection before the age of 45 years compared to those who were treated after that[69]. Adjunctive chemotherapy including vincristine, 5-fluorouracil, and cisplatin have improved the 5-year survival rate[69].

Adult pancreatobastoma, even with aggressive therapy, has poor outcomes and its optimal treatment strategy is not known. While controversial, adjuvant chemotherapy, including 5-flurororacil/doxorubicin/mitoycin and dororubicin/carboplatin, and radiotherapy may be used as palliative treatment in advanced disease[41]. The average survival in adults is only 15-18 months[37,41]. Nearly half of patients have either local invasion and/or metastasis at diagnosis[41]. The most common site for metastasis is the liver, followed by regional lymph nodes and lung[41]. BRAF and MEK inhibitors such as Dabrafenib and Trametinib showed transient response at advanced stage, given the novel IQ Motif and Sec7 Domain 1 - Rapidly Accelerated Fibrosarcoma 1 (*IQSEC1-RAF1*) fusion in pancreatoblastoma[74].

**COMPARISON OF DIGESTIVE SYSTEM BLASTOMA IN PEDIATRIC AND ADULT POPULATIONS**

To date, only 16 cases of gastroblastoma in adults have been reported. Acknowledging the limited number of cases available for comparison, pediatric patients tend to present with more pronounced clinical symptoms, such as intermittent blood in stools and significant abdominal pain[75-77]. Moreover, a distinctive demographic difference is apparent, with all reported pediatric cases occurring in males[4,75-77], as opposed to adult gastroblastoma, which affects both males and females. The remaining disease features are consistent between the two populations, and, regardless of age, patients generally show a favorable prognosis following surgical resection.

Hepatoblastoma exhibits distinct characteristics in adults. Pediatric patients typically show symptoms like abdominal swelling and pain, whereas adult symptoms are subtler[69]. Notably, about 40% of adult cases from 2013 to 2023 have underlying liver conditions like viral hepatitis or cirrhosis (Table 2), unlike the pediatric cases, which generally occur in patients without pre-existing liver disease. Histologically, adult cases also often show a more aggressive, undifferentiated histology whereas pediatric hepatoblastoma tends to show more typical epithelial and mesenchymal components including heterologous elements that indicate a favorable prognosis[69,78,79]. In adult hepatoblastoma, the presence of embryonal or undifferentiated cells often indicates a poorer prognosis[69]. Most significantly, adults are more prone to recurrence or metastasis than children despite similar treatment approaches.

Pancreatoblastoma certainly shows significant differences between adults and children. Because only 17% of pediatric cases demonstrate extrapancreatic disease at the time of diagnosis[80], presenting symptoms, like abdominal pain, palpable abdominal masses, jaundice, and vomiting, are all attributable to local tumor effect. In contrast, adults have a poorer prognosis and often present with symptoms and signs related to the more aggressive disease course, which includes frequent invasion of adjacent organs and structures as well as frequent metastases. Histology is similar in the age groups, but adult pancreatoblastomas typically contain less stroma[81]. Surgical resection is the primary treatment for both groups, often supplemented with chemotherapy and radiation therapy. However, adults generally have a poorer prognosis, frequently due to the invasion of adjacent organs or metastasis at the time of diagnosis.

**CONCLUSION**

In this review, we focus on adult digestive system blastomas, covering aspects like histopathology, molecular pathology, and treatment outcomes, along with comparisons between pediatric and adult cases. Gastroblastoma is characterized by biphasic morphology and distinctive genetic features, notably the *MALAT1-GLI1* fusion. Hepatoblastoma shows diverse morphology and commonly exhibits mutations in the Wnt-β-catenin signaling pathway. Pancreatoblastoma is marked by acinar differentiation and squamoid nests, sharing molecular pathology similarities with hepatoblastoma. Treatment mainly involves surgery, possibly with adjunct chemotherapy or radiotherapy. This review underscores the importance of ongoing research for a deeper understanding and improved management of these rare blastomas.

**REFERENCES**

1 **Miettinen M**, Dow N, Lasota J, Sobin LH. A distinctive novel epitheliomesenchymal biphasic tumor of the stomach in young adults ("gastroblastoma"): a series of 3 cases. *Am J Surg Pathol* 2009; **33**: 1370-1377 [PMID: 19718790 DOI: 10.1097/PAS.0b013e3181a6a792]

2 **McCammon N**, Dunn A, Graham R, McHugh J, Lamps L, Bresler SC, Cole T, Rottmann D. Gastroblastoma of the Pylorus: A Case Report and Review of the Literature. *Int J Surg Pathol* 2023; **31**: 1516-1521 [PMID: 36823781 DOI: 10.1177/10668969231157310]

3 **Graham RP**, Nair AA, Davila JI, Jin L, Jen J, Sukov WR, Wu TT, Appelman HD, Torres-Mora J, Perry KD, Zhang L, Kloft-Nelson SM, Knudson RA, Greipp PT, Folpe AL. Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene. *Mod Pathol* 2017; **30**: 1443-1452 [PMID: 28731043 DOI: 10.1038/modpathol.2017.68]

4 **Koo SC**, LaHaye S, Kovari BP, Schieffer KM, Ranalli MA, Aldrink JH, Michalsky MP, Colace S, Miller KE, Bedrosian TA, Leraas KM, Voytovich K, Wheeler G, Brennan P, Fitch J, Kelly BJ, McGrath SD, Miller AR, White P, Magrini V, Wilson RK, Mardis ER, Lauwers GY, Baker PB, Cottrell CE. Gastroblastoma with a novel EWSR1-CTBP1 fusion presenting in adolescence. *Genes Chromosomes Cancer* 2021; **60**: 640-646 [PMID: 34041825 DOI: 10.1002/gcc.22973]

5 **Chen C**, Lu J, Wu H. Case Report: Submucosal gastroblastoma with a novel PTCH1::GLI2 gene fusion in a 58-year-old man. *Front Oncol* 2022; **12**: 935914 [PMID: 36147912 DOI: 10.3389/fonc.2022.935914]

6 **Liu Y**, Wu H, Wu X, Feng Y, Jiang Q, Wang Q, Yang A. Gastroblastoma Treated by Endoscopic Submucosal Excavation with a Novel PTCH1::GLI2 Fusion: A Rare Case Report and Literature Review. *Curr Oncol* 2022; **29**: 8862-8873 [PMID: 36421350 DOI: 10.3390/curroncol29110697]

7 **Papry A**, Kamal M, Khalid MS. Hepatoblastoma in a child with dextrocardia and possible histopathological alteration reminiscent of hepatocellular carcinoma after neoadjuvant chemotherapy. *Clin Case Rep* 2018; **6**: 1070-1073 [PMID: 29881566 DOI: 10.1002/ccr3.1515]

8 **Marx H.** Ueber einen eigenartigen primaren Tumor der Leber. Nebst Bemerkungen zur Chorion epitheliomfrage. *Beit Path Anat*. 1904; **36**: 585-605

9 **Celotti A**, D'Amico G, Ceresoli M, Tomasoni M, Raimondo S, Baggi P, Baiocchi GL. Hepatoblastoma of the adult: A systematic review of the literature. *Surg Oncol* 2016; **25**: 339-347 [PMID: 27566042 DOI: 10.1016/j.suronc.2016.07.003]

10 **Ihssan E**, Hajar E, Salma B, Soumaya EC, Youssef M, Mouna K, Basma EK. Two Cases of Hepatoblastoma in Adults. *Clin Pathol* 2022; **15**: 2632010X221129592 [PMID: 36313585 DOI: 10.1177/2632010X221129592]

11 **Roebuck DJ**, Perilongo G. Hepatoblastoma: an oncological review. *Pediatr Radiol* 2006; **36**: 183-186 [PMID: 16404556 DOI: 10.1007/s00247-005-0064-3]

12 **Allan BJ**, Parikh PP, Diaz S, Perez EA, Neville HL, Sola JE. Predictors of survival and incidence of hepatoblastoma in the paediatric population. *HPB (Oxford)* 2013; **15**: 741-746 [PMID: 23600968 DOI: 10.1111/hpb.12112]

13 **Pila-Pérez R**, Saurith-Monterrosa JL, Rosales-Torres P, Pila-Peláez R, Artola-González JA. A case of adult hepatoblastoma. *Rev Colomb Gastroenterol* 2020; **35**: 220-225 [DOI: 10.22516/25007440.339]

14 **Agarwal M**, Kanodia S, Singh J, Giri V. Hepatoblastoma in adults with clinical symptoms and histopathological evaluation. *Pharm Anal Acta* 2023; 128-131

15 **Tsvetkova V**, Magro G, Broggi G, Luchini C, Cappello F, Caporalini C, Buccoliero AM, Santoro L. New insights in gastrointestinal "pediatric" neoplasms in adult patients: pancreatoblastoma, hepatoblastoma and embryonal sarcoma of the liver. A practical approach by GIPPI-GIPAD Groups. *Pathologica* 2022; **114**: 64-78 [PMID: 35212317 DOI: 10.32074/1591-951X-559]

16 **Omiyale AO**. Adult pancreatoblastoma: Current concepts in pathology. *World J Gastroenterol* 2021; **27**: 4172-4181 [PMID: 34326617 DOI: 10.3748/wjg.v27.i26.4172]

17 **Luchini C**, Grillo F, Fassan M, Vanoli A, Capelli P, Paolino G, Ingravallo G, Renzulli G, Doglioni C, D'Amuri A, Mattiolo P, Pecori S, Parente P, Florena AM, Zamboni G, Scarpa A. Malignant epithelial/exocrine tumors of the pancreas. *Pathologica* 2020; **112**: 210-226 [PMID: 33179623 DOI: 10.32074/1591-951X-167]

18 **Kohda E**, Iseki M, Ikawa H, Endoh M, Yokoyama J, Mukai M, Hata J, Yamazaki H, Miyauchi J, Saeki M. Pancreatoblastoma. Three original cases and review of the literature. *Acta Radiol* 2000; **41**: 334-337 [PMID: 10937753 DOI: 10.1080/028418500127345604]

19 **Chen M**, Zhang H, Hu Y, Liu K, Deng Y, Yu Y, Wu Y, Qi A, Li Y, Wen G. Adult pancreatoblastoma: A case report and clinicopathological review of the literature. *Clin Imaging* 2018; **50**: 324-329 [PMID: 29753278 DOI: 10.1016/j.clinimag.2018.05.001]

20 **Morales GES**, Payan HL, Valladares RAM, Rosado ID, Chan C. Adult pancreatoblastoma: A rare malignant tumor of the pancreas. *Ann Hepatobiliary Pancreat Surg* 2021; **25**: 436-439 [PMID: 34402449 DOI: 10.14701/ahbps.2021.25.3.436]

21 **Kulak O**, Osipov A, Hendifar AE, Nissen NN, Cox BK, Hruban RH, Hutchings DA. Pancreatoblastoma in Elderly Adults: Report of Two Patients. *Int J Surg Pathol* 2023; **31**: 772-777 [PMID: 36314453 DOI: 10.1177/10668969221133347]

22 **Rojas A**, Wodskow J, Hogg ME. Adult Pancreatoblastoma: a Rare Pancreatic Tumor. *J Gastrointest Surg* 2023; **27**: 3102-3104 [PMID: 37620658 DOI: 10.1007/s11605-023-05816-4]

23 **Abraham SC**, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, Cameron JL, Hruban RH. Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas : frequent alterations in the APC/beta-catenin pathway and chromosome 11p. *Am J Pathol* 2001; **159**: 1619-1627 [PMID: 11696422 DOI: 10.1016/S0002-9440(10)63008-8]

24 **Yamaguchi S**, Fujii T, Izumi Y, Fukumura Y, Han M, Yamaguchi H, Akita T, Yamashita C, Kato S, Sekiya T. Identification and characterization of a novel adenomatous polyposis coli mutation in adult pancreatoblastoma. *Oncotarget* 2018; **9**: 10818-10827 [PMID: 29535845 DOI: 10.18632/oncotarget.24017]

25 **Omiyale AO**. Clinicopathological review of pancreatoblastoma in adults. *Gland Surg* 2015; **4**: 322-328 [PMID: 26312218 DOI: 10.3978/j.issn.2227-684X.2015.04.05]

26 **Zouros E**, Manatakis DK, Delis SG, Agalianos C, Triantopoulou C, Dervenis C. Adult pancreatoblastoma: A case report and review of the literature. *Oncol Lett* 2015; **9**: 2293-2298 [PMID: 26137059 DOI: 10.3892/ol.2015.3001]

27 **Huang Y**, Yang W, Hu J, Zhu Z, Qin H, Han W, Wang H. Diagnosis and treatment of pancreatoblastoma in children: a retrospective study in a single pediatric center. *Pediatr Surg Int* 2019; **35**: 1231-1238 [PMID: 31338582 DOI: 10.1007/s00383-019-04524-y]

28 **Centonze G**, Mangogna A, Salviato T, Belmonte B, Cattaneo L, Monica MAT, Garzone G, Brambilla C, Pellegrinelli A, Melotti F, Testi A, Monti V, Kankava K, Gasparini P, Dagrada G, Mazzaferro V, Cotsoglou C, Collini P, Pruneri G, Milione M. Gastroblastoma in Adulthood-A Rarity among Rare Cancers-A Case Report and Review of the Literature. *Case Rep Pathol* 2019; **2019**: 4084196 [PMID: 31871808 DOI: 10.1155/2019/4084196]

29 **Wang YX**, Liu H. Adult hepatoblastoma: systemic review of the English literature. *Dig Surg* 2012; **29**: 323-330 [PMID: 23075604 DOI: 10.1159/000342910]

30 **Wey EA**, Britton AJ, Sferra JJ, Kasunic T, Pepe LR, Appelman HD. Gastroblastoma in a 28-year-old man with nodal metastasis: proof of the malignant potential. *Arch Pathol Lab Med* 2012; **136**: 961-964 [PMID: 22849746 DOI: 10.5858/arpa.2011-0372-CR]

31 **Pinto DN VJ**, Gomes D, Brito T, Leite M, Monteiro C, Matos C, Fazeres F, Lopes L, Midões A. Gastroblastoma described in adult patient. *Int J Case Rep Images* 2019; **10**: 100995 [DOI: 10.5348/100995Z01DP2019CR]

32 **Yamazaki M**, Ryu M, Okazumi S, Kondo F, Cho A, Okada T, Takayama W, Kawashima T, Furuki A, Hirata T. Hepatoblastoma in an adult A case report and clinical review of literatures. *Hepatol Res* 2004; **30**: 182-188 [PMID: 15588785 DOI: 10.1016/j.hepres.2004.08.001]

33 **Al-Jiffry BO**. Adult hepatoblastoma: A case report and literature review. *Int J Surg Case Rep* 2013; **4**: 204-207 [PMID: 23279808 DOI: 10.1016/j.ijscr.2012.10.019]

34 **Wu M**, Lin J, Liu Z, Huang Z, Wang R. CT, MRI, and (18)F-FDG PET/CT imaging features of seven cases of adult pancreatoblastoma. *BMC Med Imaging* 2022; **22**: 228 [PMID: 36581821 DOI: 10.1186/s12880-022-00958-4]

35 **Li J**, Peng C, Fan X, Wang L, Wang J. Adult pancreatoblastoma: a case report. *J Int Med Res* 2021; **49**: 3000605211039565 [PMID: 34461770 DOI: 10.1177/03000605211039565]

36 **Zhang X**, Ni SJ, Wang XH, Huang D, Tang W. Adult pancreatoblastoma: clinical features and Imaging findings. *Sci Rep* 2020; **10**: 11285 [PMID: 32647222 DOI: 10.1038/s41598-020-68083-2]

37 **Cavallini A**, Falconi M, Bortesi L, Crippa S, Barugola G, Butturini G. Pancreatoblastoma in adults: a review of the literature. *Pancreatology* 2009; **9**: 73-80 [PMID: 19077457 DOI: 10.1159/000178877]

38 **Du E**, Katz M, Weidner N, Yoder S, Moossa AR, Shabaik A. Ampullary pancreatoblastoma in an elderly patient: a case report and review of the literature. *Arch Pathol Lab Med* 2003; **127**: 1501-1505 [PMID: 14567752 DOI: 10.5858/2003-127-1501-APIAEP]

39 **Yang X**, Wang X. Imaging findings of pancreatoblastoma in 4 children including a case of ectopic pancreatoblastoma. *Pediatr Radiol* 2010; **40**: 1609-1614 [PMID: 20686762 DOI: 10.1007/s00247-010-1776-6]

40 **Qureshi SS**, Bhagat M, Kurkure PA, Kembhavi SA. Ectopic Cushing syndrome secondary to recurrent pancreatoblastoma in a child: Lessons learnt. *J Cancer Res Ther* 2015; **11**: 1027 [PMID: 26881602 DOI: 10.4103/0973-1482.151854]

41 **Salman B**, Brat G, Yoon YS, Hruban RH, Singhi AD, Fishman EK, Herman JM, Wolfgang CL. The diagnosis and surgical treatment of pancreatoblastoma in adults: a case series and review of the literature. *J Gastrointest Surg* 2013; **17**: 2153-2161 [PMID: 24081396 DOI: 10.1007/s11605-013-2294-2]

42 **Kletter GB**, Sweetser DA, Wallace SF, Sawin RS, Rutledge JC, Geyer JR. Adrenocorticotropin-secreting pancreatoblastoma. *J Pediatr Endocrinol Metab* 2007; **20**: 639-642 [PMID: 17642425 DOI: 10.1515/JPEM.2007.20.5.639]

43 **Castri F**, Ravegnini G, Lodoli C, Fiorentino V, Abatini C, Giustiniani MC, Angelini S, Ricci R. Gastroblastoma in old age. *Histopathology* 2019; **75**: 778-782 [PMID: 31287169 DOI: 10.1111/his.13951]

44 **Fernandes T**, Silva R, Devesa V, Lopes JM, Carneiro F, Viamonte B. AIRP best cases in radiologic-pathologic correlation: gastroblastoma: a rare biphasic gastric tumor. *Radiographics* 2014; **34**: 1929-1933 [PMID: 25384293 DOI: 10.1148/rg.347130103]

45 **Poizat F**, de Chaisemartin C, Bories E, Delpero JR, Xerri L, Flejou JF, Monges G. A distinctive epitheliomesenchymal biphasic tumor in the duodenum: the first case of duodenoblastoma? *Virchows Arch* 2012; **461**: 379-383 [PMID: 22961103 DOI: 10.1007/s00428-012-1307-y]

46 **Toumi O**, Ammar H, Korbi I, Ayed M, Gupta R, Nasr M, Salem R, Hadhri R, Zayed S, Noomen F, Zakhama A, Zouari K. Gastroblastoma, a biphasic neoplasm of stomach: A case report. *Int J Surg Case Rep* 2017; **39**: 72-76 [PMID: 28822310 DOI: 10.1016/j.ijscr.2017.06.061]

47 **Gong C**, Xu J, Qiao S, Zhang X, Yi M. Gastroblastoma without GLI1 and EWSR1 gene breaks. *World J Surg Oncol* 2023; **21**: 274 [PMID: 37658451 DOI: 10.1186/s12957-023-03159-7]

48 **Zhu N**, Hou YY, Ge XW, Yao JM. A small volume gastroblastoma occurred in a 65-year-old woman. *Zhenduan Binglixue Zazhi* 2018; **25**: 2 [10.3969/j.issn.1007-8096.2018.04.023]

49 **Pagarigan AKL**, Mendoza PGL. Adult hepatoblastoma: making the challenging distinction from hepatocellular carcinoma. *J Liver Cancer* 2023; **23**: 219-224 [PMID: 37384033 DOI: 10.17998/jlc.2023.02.24]

50 **Park KW**, Seo CJ, Yun DY, Kim MK, Kim BS, Han YS, Oh HK, Lee CH. A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult. *Clin Mol Hepatol* 2015; **21**: 300-308 [PMID: 26523273 DOI: 10.3350/cmh.2015.21.3.300]

51 **Caso-Maestro Ó**, Justo-Alonso I, Cambra-Molero F, Manrique-Municio A, Calvo-Pulido J, Jiménez-Romero C. Adult hepatoblastoma: case report with adrenal recurrence. *Rev Esp Enferm Dig* 2013; **105**: 638-639 [PMID: 24641466 DOI: 10.4321/S1130-01082013001000014]

52 **Cienfuegos JA**, Labiano T, Pedano N, Zozaya GN, Martí-Cruchaga P, Panizo Á, Rotellar F. Adult hepatoblastoma. *Rev Esp Enferm Dig* 2013; **105**: 229-231 [PMID: 23859453 DOI: 10.4321/S1130-01082013000400009]

53 **Zhang Q**, Ming J, Zhang S, Guo D, Qiu X. A rare case of adult hepatoblastoma with neuroendocrine differentiation misdiagnosed as neuroendocrine tumor. *Int J Clin Exp Pathol* 2013; **6**: 308-313 [PMID: 23330017]

54 **Celotti A**, Baiocchi GL, Ceresoli M, Bartoli M, Ulinici S, Portolani N. Hepatoblastoma of the adult with pericardial metastasis: A case report. *Int J Surg Case Rep* 2016; **20**: 80-83 [PMID: 26826931 DOI: 10.1016/j.ijscr.2016.01.010]

55 **Goikoetxea Urdiain A**, Sánchez Acedo P, Mateo Retuerta J, Tarifa Castilla A, Zazpe Ripa C, Herrera Cabezón J. [Adult hepatoblastoma. A case report]. *An Sist Sanit Navar* 2016; **39**: 301-304 [PMID: 27599957 DOI: 10.23938/ASSN.0264]

56 **Dave M**, Vignesh K, Bordi S, Saini H, Sukhwal D, Sareen M. Hepatoblastoma: A rare presentation in elderly. *BJKines-NJBAS* 2019; **11**: 63-67

57 **Machado I**, López-Guerrero JA, Fernandez A, López R, García Casado Z, Ferrandez A, Llombart-Bosch A, Charville GW. Adult Pancreatoblastoma: Report of 3 new Cases With Genetic Diversity and Autopsy Findings. *Int J Surg Pathol* 2023; **31**: 896-906 [PMID: 36573045 DOI: 10.1177/10668969221133351]

58 **Hussain A**, Farrukh J. Adult Pancreatoblastoma: An Uncommon Pancreatic Malignancy. *Cureus* 2023; **15**: e48063 [PMID: 38046486 DOI: 10.7759/cureus.48063]

59 **Suemitsu Y**, Ono Y, Mizukami Y, Ye J, Yamakawa K, Takamoto T, Nakano-Narusawa Y, Mukai Y, Takamatsu M, Nakazawa A, Mino-Kenudson M, Kumasaka T, Matsuda Y. A Case of Adult Pancreatoblastoma With Novel APC Mutation and Genetic Heterogeneity. *Front Oncol* 2021; **11**: 725290 [PMID: 34513702 DOI: 10.3389/fonc.2021.725290]

60 **Raoul JL**, Oziel-Taieb S, Lecomte T, Adelaide J, Guille A, Chaffanet M, Poizat F, Heymann MF, Barbier L, Bertucci F. Case Report: Two Cases of Metastatic Pancreatoblastoma in Adults: Efficacy of Folfirinox and Implication of the Wnt/β-Catenin Pathway in Genomic Analysis. *Front Oncol* 2021; **11**: 564506 [PMID: 33796447 DOI: 10.3389/fonc.2021.564506]

61 **Elghawy O**, Wang JS, Whitehair RM, Grosh W, Kindwall-Keller TL. Successful treatment of metastatic pancreatoblastoma in an adult with autologous hematopoietic cell transplant. *Pancreatology* 2021; **21**: 188-191 [PMID: 33199137 DOI: 10.1016/j.pan.2020.10.049]

62 **Snyder MH**, Ampie L, Mandell JW, Helm GA, Syed HR. A Rare Case of Pancreatoblastoma with Intracranial Seeding. *World Neurosurg* 2020; **142**: 334-338 [PMID: 32622062 DOI: 10.1016/j.wneu.2020.06.210]

63 **Morrissey G**, Cohen P, Julve M. Rare case of adult pancreatoblastoma. *BMJ Case Rep* 2020; **13** [PMID: 32265211 DOI: 10.1136/bcr-2019-233884]

64 **Berger AK**, Mughal SS, Allgäuer M, Springfeld C, Hackert T, Weber TF, Naumann P, Hutter B, Horak P, Jahn A, Schröck E, Haag GM, Apostolidis L, Jäger D, Stenzinger A, Fröhling S, Glimm H, Heining C. Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease. *Pancreatology* 2020; **20**: 425-432 [PMID: 32156527 DOI: 10.1016/j.pan.2020.02.017]

65 **Liu ET**, Liu C, Wang HL, Sun TT, Wang SX. Adult Pancreatoblastoma With Liver Metastasis Diagnosed by 18F-FDG PET/CT and 2 Years' Postoperative Follow-up. *Clin Nucl Med* 2020; **45**: e24-e28 [PMID: 31274558 DOI: 10.1097/RLU.0000000000002684]

66 **Yin SM,** Liu YW, Chou FF, Kuo FY, Tsang LC. Complete Surgical Resection and Aggressive Treatment for Liver Metastasis May Be Beneficial to Adult Patients With Pancreatoblastoma: A Case Report and Review of Literature. *Int Surg* 2019; **104**: 149-154 [DOI: 10.9738/INTSURG-D-19-00006.1]

67 **Reid MD**, Bhattarai S, Graham RP, Pehlivanoglu B, Sigel CS, Shi J, Saqi A, Shirazi M, Xue Y, Basturk O, Adsay V. Pancreatoblastoma: Cytologic and histologic analysis of 12 adult cases reveals helpful criteria in their diagnosis and distinction from common mimics. *Cancer Cytopathol* 2019; **127**: 708-719 [PMID: 31581358 DOI: 10.1002/cncy.22187]

68 **Nunes G**, Coelho H, Patita M, Barosa R, Pinto Marques P, Roque Ramos L, Brito MJ, Tomaz A, Fonseca J. Pancreatoblastoma: an unusual diagnosis in an adult patient. *Clin J Gastroenterol* 2018; **11**: 161-166 [PMID: 29285688 DOI: 10.1007/s12328-017-0812-6]

69 **Rougemont AL**, McLin VA, Toso C, Wildhaber BE. Adult hepatoblastoma: learning from children. *J Hepatol* 2012; **56**: 1392-1403 [PMID: 22326463 DOI: 10.1016/j.jhep.2011.10.028]

70 **Musick SR**, Smith M, Rouster AS, Babiker HM. Hepatoblastoma. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan- [PMID: 30521216]

71 **Hager J**, Sergi CM. Hepatoblastoma. In: Liver Cancer [Internet]. Brisbane (AU): Exon Publications; 2021-Apr-6 [PMID: 33905194]

72 **Bell D**, Ranganathan S, Tao J, Monga SP. Novel Advances in Understanding of Molecular Pathogenesis of Hepatoblastoma: A Wnt/β-Catenin Perspective. *Gene Expr* 2017; **17**: 141-154 [PMID: 27938502 DOI: 10.3727/105221616X693639]

73 **Reissig TM**, Uhrig S, Jost PJ, Luchini C, Vicentini C, Liffers ST, Allgäuer M, Adsay V, Scarpa A, Lawlor RT, Fröhling S, Stenzinger A, Klöppel G, Schildhaus HU, Siveke JT. MCL1 as putative target in pancreatoblastoma. *Virchows Arch* 2022; **481**: 265-272 [PMID: 35668118 DOI: 10.1007/s00428-022-03349-w]

74 **Goto H**, Koga Y, Kohashi K, Ono H, Takemoto J, Matsuura T, Tajiri T, Ihara K, Oda Y, Ohga S. Pancreatoblastoma with a novel fusion gene of IQSEC1-RAF1. *Pediatr Blood Cancer* 2023; **70**: e30155 [PMID: 36519595 DOI: 10.1002/pbc.30155]

75 **Shin DH**, Lee JH, Kang HJ, Choi KU, Kim JY, Park DY, Lee CH, Sol MY, Park JH, Kim HY, Montgomery E. Novel epitheliomesenchymal biphasic stomach tumour (gastroblastoma) in a 9-year-old: morphological, ultrastructural and immunohistochemical findings. *J Clin Pathol* 2010; **63**: 270-274 [PMID: 20203230 DOI: 10.1136/jcp.2009.074104]

76 **Ma Y**, Zheng J, Zhu H, Dong K, Zheng S, Xiao X, Chen L. Gastroblastoma in a 12-year-old Chinese boy. *Int J Clin Exp Pathol* 2014; **7**: 3380-3384 [PMID: 25031764]

77 **Feng J**, Ling C, Xue Y, Li J. Gastroblastoma in a 5-year-old child: a case report and literature review. *Front Oncol* 2023; **13**: 1198762 [PMID: 38023244 DOI: 10.3389/fonc.2023.1198762]

78 **Kasai M**, Watanabe I. Histologic classification of liver-cell carcinoma in infancy and childhood and its clinical evaluation. A study of 70 cases collected in Japan. *Cancer* 1970; **25**: 551-563 [PMID: 4313652 DOI: 10.1002/1097-0142(197003)25:3<551::AID-CNCR2820250309>3.0.CO;2-5]

79 **González-Crussi F**, Upton MP, Maurer HS. Hepatoblastoma. Attempt at characterization of histologic subtypes. *Am J Surg Pathol* 1982; **6**: 599-612 [PMID: 6295193]

80 **Dhebri AR**, Connor S, Campbell F, Ghaneh P, Sutton R, Neoptolemos JP. Diagnosis, treatment and outcome of pancreatoblastoma. *Pancreatology* 2004; **4**: 441-51; discussion 452-3 [PMID: 15256806 DOI: 10.1159/000079823]

81 **Klimstra DS**, Wenig BM, Adair CF, Heffess CS. Pancreatoblastoma. A clinicopathologic study and review of the literature. *Am J Surg Pathol* 1995; **19**: 1371-1389 [PMID: 7503360 DOI: 10.1097/00000478-199512000-00005]

**Footnotes**

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: Https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** January 1, 2024

**First decision:** January 25, 2024

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Yang JS, China **S-Editor:** Li L **L-Editor:** A **P-Editor:**

**Figure Legends**

A close-up of a pink and purple tissue

Description automatically generatedA collage of images of cells

Description automatically generated

**Figure 1 Gastroblastoma in a 19-year-old patient.** A and B: The tumor involves the muscularis propria of the antrum (20 ×); C: The tumor shows a biphasic histology with spindle stromal component more prominent in left lower of the image (40 ×); D: The high-magnification image shows the epithelial cells with glandular formation (400 ×); E: Cytoketatin staining (AE1/3) labels the epithelial cells but not the mesenchymal component (200 ×).

A close-up of a cell

Description automatically generated

**Figure 2 Mixed epithelial mesenchymal hepatoblastoma in an adult patient, showing a heterogeneous mix of epithelial and mesenchymal components.** Well differentiated fetal-type epithelial component is characterized by their eosinophilic cytoplasm and cords or nests-like growth reminiscent of normal liver architecture. The mesenchymal part shows heterologous osteoid elements (100 ×).

A close-up of a microscope

Description automatically generated

**Figure 3 Pancreatoblastoma in the pancreatic head of a 42-year-old male patient.** A: The tumor is composed of acinar and ribbonlike morphology composed of relatively monotonous cells with basophilic nuclei, mimicking a pancreatic endocrine tumor (100 ×); B: In a few foci, squamoid nests, consisting of circumscribed whorled nests of polygonal cells with abundant eosinophilic cytoplasm and a squamous appearance, are present (200 ×).

**Table 1 Summary of reported cases of adult gastroblastoma**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Age/sex | Location | Molecular alteration (s) | Treatment | Follow-up | Recurrence or metastasis |
| Castri *et al*[43], 2019 | 74/M | Gastric antrum | *MALAT1::GLI1* | Partial gastrectomy | 5 years | Yes, recurrence at 5 years |
| Centonze *et al*[28], 2019 | 43/F | Gastric antrum | Not performed | Partial gastrectomy | 100 months | No |
| Fernandes *et al*[44], 2014 | 19/F | Gastric antrum | Not performed | Partial distal gastrectomy | 20 months | No |
| Graham *et al*[3], 2017 | 27/M | Stomach | *MALAT1::GLI1* | Partial gastrectomy | 12 months | No |
| Graham *et al*[3], 2017 | 56/F | Stomach | *MALAT1::GLI1* | N/A | N/A | Metastasis to liver |
| McCammon *et al*[2], 2023 | 26/M | Gastric pylorus extending through the first and second portions of the duodenum. | *MALAT1::GLI1* | Tumor resection from the mucosa of pylorus and duodenum | 2 months | No |
| Miettinen *et al*[1], 2009 | 30/M | Gastric antrum | Not performed | Antrectomy, postoperative radiation | 14 years | No |
| Miettinen *et al*[1], 2009 | 27/F | Gastric body | Not performed | Partial gastrectomy | 5 years | No |
| Miettinen *et al*[1], 2009 | 19/M | Gastric body | Not performed | Subtotal gastrectomy | 3.5 years | No |
| Pinto *et al*[31], 2019 | 53/F | Gastric antrum | Not performed | Partial gastrectomy | 18 months | No |
| Poizat *et al*[45], 2012 | 22/F | Duodenum | Not performed | Partial resection of the distal duodenum | 16 months | No |
| Toumi *et al*[46], 2017 | 29/F | Gastric body | Not performed | Partial gastrectomy + splenectomy | 6 months | Local recurrence after 6 months |
| Wey *et al*[30], 2012 | 28/M | Distal stomach | *MALAT1::GLI1\** | Preoperative chemotherapy + partial gastrectomy | 3 months | Metastasis to lymph nodes, liver, pelvis; clinically stable at 3 months |
| Gong *et al*[47], 2023 | 19/M | Gastric antrum | No gene break rearrangement detected by FISH | Partial gastrectomy | 19 months | No |
| Zhu *et al*[48], 2018 | 65/F | Gastric body | Not performed | Full-thickness resection of the gastric wall | 4 years | No |
| Chen *et al*[5], 2022 and Liu *et al*[6], 2022 | 58/M | Gastric body | *PTCH1::GLI2* | Endoscopic submucosal dissection | 1 year | No |

F: Female; M: Male; N/A: Not applicable.

**Table 2 Summary of reported cases of adult hepatoblastoma from recent 10 years (2013-2023)**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Age/sex | Location | Hepatitis B | Liver cirrhosis | AFP | Metastasis at diagnosis | Histology | Treatment | Follow-up | Recurrence or metastasis |
| Pagarigan *et al*[49], 2023 | 49/F | Right hepatic lobe | HBsAg (+); anti-HBc (+) | Yes | > 50000 ng/mL | No | Mixed | Surgical resection + postoperative chemotherapy | 4 months | Recurrence |
| Ihssan *et al*[10], 2022 | 26/F | Right Hepatic lobe | No | No | 2275 ng/mL | No | Epithelial (the mixed fetal and embryonic pattern) | Surgical resection | N/A | N/A |
| Ihssan *et al*[10], 2022 | 50/M | Entire liver | No | No | 6386 ng/mL | No | Mixed | N/A | N/A | N/A |
| Park *et al*[50], 2015 | 36/F | Right hepatic lobe | HBsAg (+); anti-HBc (+) | Yes | 676.5 ng/mL | No | Mixed | Surgical resection + postoperative chemotherapy | 5 months | Intraperitoneal metastasis, died |
| Caso-Maestro *et al*[51], 2013 | 27/M | Right hepatic lobe | HBsAg +, HBcAb +, HBeAb + | No | 1166000 ng/mL |  | Mixed | Surgical resection | 27 months | Left adrenal recurrence followed by total adrenalectomy; alive |
| Al-Jiffry *et al*[33], 2013 | 22/M | Right hepatic lobe | No | No | Normal | Diaphragm and pericardial; infiltration; IVC infiltration | Mixed | Surgical resection | 16 d | Died |
| Cienfuegos *et al*[52], 2013 | 37/F | Segment 5 and 6 of the liver | HBsAg +, HBcAb +, HBeAb + | Yes | 1556.3 ng/mL | No | Mixed | Surgical resection | 10 months | Recurrence and died |
| Zhang *et al*[53], 2013 | 32/F | Left hepatic lobe | No | No | Normal | No | Epithelial, neuroendocrine differentiation | N/A | N/A | N/A |
| Park *et al*[50], 2015 | 36/F | Right hepatic lobe | HBsAg +, HBcAb +, HBeAb + |  | 676.5 ng/mL | No | Mixed | Surgical resection + postoperative chemotherapy | 12 months | Left subphrenic area metastasis; died |
| Celotti *et al*[54], 2016 | 68/M | Left hepatic lobe | No | No | 1231 ng/mL | Pericardial metastasis | Mixed | Left lobectomy +; diaphragm resection + extended pericardiectomy | 21 months | No recurrence |
| Urdiain *et al*[55], 2019 | 65/M | Right hepatic lobe | No | No | N/A | No | Epithelial | Surgical resection | 10 months | Recurrence, died |
| Dave *et al*[56], 2019 | 84/M | Left hepatic lobe | N/A | N/A | 708 IU/mL | Metastatic to left lower bronchus, left descending pulmonary artery and left descending pulmonary vein | Mixed | N/A | N/A | N/A |

AFP: Alpha-fetoprotein; F: Female; M: Male; HBsAg: Hapatitis B surface Antigen; HBcAb: Hepatitis B core antibody; HBeAb: Hepatitis B e-antibody; N/A: Not applicable; IVC: Integrated visual computing.

**Table 3 Summary of reported cases of adult pancreatoblastoma from recent 5 years (2018-2023)**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Age/sex | Location | Metastasis before treatment | Treatment | Follow-up (months/years) | Recurrence/metastasis | Outcome |
| Rojas *et al*[22], 2023 | 45/F | Pancreatic tail | No | Pancreatectomy and splenectomy; Chemotherapy; stem cell transplant | 3 months | Liver metastasis | N/A |
| Machado *et al*[57], 2023 | 3 patients (2F, 1M); 2avg age: 51 | Tail and body of pancreas | Liver and lung metastasis | Surgical resection | 6 years 2 months | Regional or distant metastasis | 2 died; 1 alive after 6 years 2 months following surgery |
| Hussain and Farrukh[58], 2023 | 75/M | Pancreatic head | Liver metastasis | Chemotherapy; stent insertion | 5 months | No | Stable |
| Wu *et al*[34], 2022 | 7 patients (2M, 5F); avg age: 56.71 | Pancreatic head (*n* = 3), tail (*n* = 2), gastric antrum (*n* = 1), neck (*n* = 1) | Liver (*n* = 2), Lymph node (*n* = 2), kidney adrenal (*n* = 1) | N/A | Not reported in 3 cases, 24, 26, 4, 4 months in others | N/A | 4 patients died during follow-up |
| Suemitsu *et al*[59], 2021 | 74/M | Tail of pancreas | No | Open distal pancreatectomy and splenectomy | 36 months | No | Recurrence-free |
| Li *et al*[35], 2021 | 60/F | Tail of the pancreas | Right liver metastasis | Resection and chemotherapy | 16 months | N/A | Death |
| Morales *et al*[20], 2021 | 76/M | Pancreatic head | Lymphovascular and perineural invasion | Chemotherapy | 32 months | No | Stable |
| Raoul *et al*[60], 2021 | 33/F | Pancreas | Invading gastric wall | Pancreatectomy, Chemotherapy | 14 months | Liver metastasis | Stable |
| Raoul *et al*[60], 2021 | 33/F | Pancreatic tail | Liver metastasis | Chemotherapy | 20 months | No | Stable |
| Elghawy *et al*[61], 2021 | 23/F | Pancreatic tail | Liver metastasis | Chemotherapy; autologous hematopoietic cell transplant | 57 months | N/A | Stable |
| Zhang *et al*[36], 2020 | 7 patients (7M); Avg age: 44.71 | 3 in pancreatic head; 1 in neck; 1 in body; 2 in tail | Only 1 patient liver metastasis | Surgical resection | 1.5 months, 6 months, 8 months, 8.5 months, 10 months, 2 years, 4 years | 3 patients developing liver metastasis | Alive = 2, lost to follow-up = 5 |
| Snyder *et al*[62], 2020 | 28/F | N/A | Liver metastasis | Chemotherapy; left suboccipital craniotomy | More than 51 months | Brain metastasis | Alive |
| Morrissey *et al*[63], 2020 | 69/M | Pancreatic head | No | Adjuvant chemotherapy; Surgical resection | 10 wk | No | Alive (tumor-free) |
| Berger *et al*[64], 2020 | 32/F | Pancreatic head | Liver metastasis | Pancreaticoduodenectomy and Lymphonodectomy; Right hemihepatectomy for liver metastasis; Chemotherapy | 14 months | Lung metastasis | Died |
| Berger *et al*[64], 2020 | 19/M | Pancreas | No | Chemotherapy, pylorus-preserving pancreaticoduodenectomy; autologous stem cell transplantation | 24 months | Liver and abdominal lymph node metastasis | Died |
| Berger *et al*[64], 2020 | 30/M | Pancreatic head | No | Complete pancreatectomy; adjuvant chemotherapy: Immunotherapy | 17 months | Liver metastasis | Died |
| Berger *et al*[64], 2020 | 20/F | Pancreatic tail | Diffuse liver metastasis | Chemotherapy | 14 months | N/A | Died |
| Liu *et al*[65], 2020 | 49/M | Pancreatic tail | Liver metastasis | Complete resection of the primary and metastatic lesions. | 2 years | N/A | Stable |
| Yin *et al*[66], 2019 | 27/F | Pancreatic head | No | Pancreatoduodenectomy | 1 year and 10 months | Liver metastasis | Alive |
| Reid *et al*[67], 2019 | 11 adults (6M, 5F); median age, 45 years | Pancreatic head (*n* = 7), tail (*n* = 4) | 3 patients | Not mentioned in detail; suggestive of surgical resection | Average 39.8 months | 4 cases developing metastasis | Alive = 6, died = 5 |
| Chen *et al*[19], 2018 | 26/M | Head of pancreas | Liver metastasis | TACE | 4 years | No | Died |
| Yamaguchi *et al*[24], 2018 | 37/F | Pancreas head | No | Pancreaticoduodenectomy and chemotherapy | 13 months | Liver metastasis | Died |
| Nunes *et al*[68], 2018 | 31/M | Pancreatic tail | Yes | Hemodialysis | 3 months | N/A | Died |

TACE: Transcatheter hepatic arterial chemoembolization; N/A: Not applicable; M: Male; F: Female.